Novo files for hemophilia drug OK; Fate Therapeutics names new CEO; Shenzhen Hepalink invests in ProMetic;

 @FierceBiotech: New special report on 10 promising therapeutic vaccines in 2012. Feature | Follow @FierceBiotech

 @JohnCFierce: Genzyme, likely to get some tough safety questions on Kynamro at this week's FDA panel. More | Follow @JohnCFierce

 @RyanMFierce: Piramal is poised to be a big consolidator in pharma services/manufacturing, but apparently only at the right price. More | Follow @RyanMFierce

> Novo Nordisk ($NVO) has filed for regulatory approval of its hemophilia drug Turoctocog Alfa in the U.S. and Europe. Report

> Fate Therapeutics named Christian Weyer as its new president and chief executive officer. Release

> China's Shenzhen Hepalink Pharmaceutical is making a $10 million investment in Canada's ProMetic Life Sciences while striking two R&D pacts worth up to $21 million. Story

Pharma News

@FiercePharma: Other compounded drugs may be tied into meningitis outbreak, FDA says. Another NECC steroid + NECC heart drug. More | Follow @FiercePharma

> J&J credits Remicade, Zytiga for 7% hike in Q3 drug sales. Story

> Roche sales hike sums up pharma hopes for cancer, emerging markets. Article

> India kicks branded generics to the curb. Report

Medical Device News

 @FierceMedDev: JNJ pulled in $7.1 billion from medical devices and diagnostics in Q3, a 12.5% jump. More | Follow @FierceMedDev

 @MarkHFierce: Patients in India thrived with used ICD implants. Can this be done on a broader scale? More | Follow @MarkHFierce

 @DamianFierce: Medtronic is buying a $66.2M stake in China's LifeTech Scientific, makers of cardiovascular devices. More | Follow @DamianFierce

> Amid Dx sales growth, Roche Diagnostics considers another buy. News

> Lanx draws $8.7M for spinal fusion device development. Item

Biotech Research News

> NIH funds Advanced Cancer Therapeutics' preclinical brain cancer drug work. Report

> Scientists flee $3B Texas cancer research fund. Item

> Alnylam, Tel Aviv U develop RNAi drugs to fight rare blood cancer. Article

> Alzheimer's drug builds new brain cell connections in rats. News

> Scientists build neural-like stem cells from mouse muscle tissue. Story

Pharma Manufacturing News

> GSK cancels plans to close Stiefel plant in Ireland. Story

> Cinven continues generics deal spree with Amdipharm buy. Article

> Teva Pharma opens $110M plant in Hungary. News

> Analysis: Compounding groups fought FDA oversight before NECC disaster. Report

And Finally... Postdoctoral Research Fellow Devin Koestler and colleagues are investigating the potential use of white blood cell variation as a diagnostic and research tool for cancer. Release


Suggested Articles

Gilead Chief Scientific Officer and R&D chief John McHutchison, M.D., is leaving one year after he replaced R&D lead Norbert Bischofberger, Ph.D.

Astellas will develop Frequency's hearing loss drug outside the U.S. in exchange for $80 million upfront and the promise of $545 million down the line.

Inovio Pharmaceuticals is cutting 28% of its workforce and swinging the ax to a bladder cancer test.